. Author manuscript; available in PMC: 2014 Nov 5.

Published in final edited form as: Clin Cancer Res. 2010 Dec 1;16(23):5796–5804. doi: 10.1158/1078-0432.CCR-10-0292

Table 2.

A. Univariate and partition analysis biomarker output data from training cohort
Biomarker	p-value^a	AER^b	Relative Risk	Odds Ratio	Positive Power	Negative Power	AUC^c
FANCD2	0.001	0.3	3.83	7.52	0.57	0.85	0.71
XPF	0.005	0.3	2.66	4.77	0.56	0.79	0.67
PAR	0.293	0.35	1.64	2.29	0.5	0.7	0.54
pMK2	0.012	0.42	3.02	4.68	0.45	0.85	0.65
PARP1	0.259	0.41	1.5	1.88	0.43	0.71	0.53
MLH1	0.017	0.37	2.34	3.61	0.48	0.79	0.61
P53	0.024	0.35	2.06	3.11	0.5	0.76	0.6
Ki67	0.070	0.39	2.36	3.5	0.45	0.81	0.59
4-marker	9.05E-07	0.22	3.52	16.11	0.83	0.76	na

B. Univariate and multivariate analysis of clinical factors and biomarker panel in all patients for recurrence
	Univariate analysis				Multivariate analysis
	Value	95% CI		p-value	Value	95% CI		p-value
4-marker	5.8	2.84	11.9	1.50E-06	4.74	1.5	15	0.0017
Age	1	0.97	1.03	0.77	1.01	0.97	1.06	0.43
T stage	1.69	1.17	2.43	4.10E-03	1.54	0.83	2.85	0.038
N stage	2.15	1.44	3.22	1.90E-05	1.12	0.55	2.3	0.28
Tx	0.98	0.68	1.41	0.91	1.32	0.78	2.23	0.21
Chemo	1.23	0.87	1.74	0.24	1.1	0.65	1.87	0.8
BRCA	1.34	0.74	2.41	0.33	1.26	0.61	2.62	0.4
LVI	4.24	1.96	9.17	2.40E-04	1.57	0.55	4.46	0.36
Grade	55.6	4.50E-09	6.90E+11	0.73	167.4	3.00E-15	1.00E+19	0.75

^a.

p-value for separation of Early Recurrence from Late Recurrence groups;

^b.

AER, Apparent Error Rate

^c.

AUC, Area Under Curve value from Receiver Operator Characteristics; &. Ki67 quantity score, weighting used is 0111 for 0,1+,2+,3+ bins #, 4-marker, multi-marker model containing FANCD2, XPF, PAR, pMK2